141 related articles for article (PubMed ID: 8069184)
1. Phenotypic characteristics of acute megakaryocytic leukemia and transient abnormal myelopoiesis.
Yumura-Yagi K; Hara J; Tawa A; Kawa-Ha K
Leuk Lymphoma; 1994 May; 13(5-6):393-400. PubMed ID: 8069184
[TBL] [Abstract][Full Text] [Related]
2. Mixed phenotype of blasts in acute megakaryocytic leukaemia and transient abnormal myelopoiesis in Down's syndrome.
Yumura-Yagi K; Hara J; Kurahashi H; Nishiura T; Kaneyama Y; Osugi Y; Sakata N; Inoue M; Tawa A; Okada S
Br J Haematol; 1992 Aug; 81(4):520-5. PubMed ID: 1390239
[TBL] [Abstract][Full Text] [Related]
3. Transient abnormal myelopoiesis in Down's syndrome.
Kurahashi H; Hara J; Yumura-Yagi K; Tawa A; Kawa-Ha K
Leuk Lymphoma; 1992 Dec; 8(6):465-75. PubMed ID: 1297480
[TBL] [Abstract][Full Text] [Related]
4. Expression of megakaryocytic and myeloid markers in blasts of transient abnormal myelopoiesis in a stillbirth with Down syndrome: report of histopathological findings of an autopsy case.
Ishigaki H; Miyauchi J; Yokoe A; Nakayama M; Yanagi T; Taga T; Ohta S; Itoh Y; Ogasawara K
Hum Pathol; 2011 Jan; 42(1):141-5. PubMed ID: 20970166
[TBL] [Abstract][Full Text] [Related]
5. Target cell of leukemic transformation in acute megakaryoblastic leukemia.
Koike T; Urushiyama M; Narita M; Saitoh H; Ishida F; Imashuku S; Morioka Y; Utsumi J; Ishizuka T; Tsuruta T
Am J Hematol; 1990 Aug; 34(4):252-8. PubMed ID: 2164321
[TBL] [Abstract][Full Text] [Related]
6. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
[TBL] [Abstract][Full Text] [Related]
7. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
[TBL] [Abstract][Full Text] [Related]
8. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
[TBL] [Abstract][Full Text] [Related]
9. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
10. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
11. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
Anoop P; Atra A
J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
[TBL] [Abstract][Full Text] [Related]
12. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate.
Polski JM; Galambos C; Gale GB; Dunphy CH; Evans HL; Batanian JR
J Pediatr Hematol Oncol; 2002 Jan; 24(1):50-4. PubMed ID: 11902741
[TBL] [Abstract][Full Text] [Related]
13. Pan myeloid antigen-negative pediatric acute megakaryoblastic leukemia.
Cetin N; Lorsbach RB
Pediatr Blood Cancer; 2014 Nov; 61(11):2089-91. PubMed ID: 24962432
[TBL] [Abstract][Full Text] [Related]
14. Aberrant progenitors common to megakaryocytic and myeloid cells in a Down's infant with transient abnormal myelopoiesis.
Sato A; Imaizumi M; Noro T; Ichinohasama R; Saito T; Yoshinari M; Suwabe N; Suzuki H; Koizumi Y; Cui Y
Leuk Res; 1995 Nov; 19(11):811-5. PubMed ID: 8551797
[TBL] [Abstract][Full Text] [Related]
15. The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
Miyauchi J; Kawaguchi H
Leuk Res; 2021 Jun; 105():106570. PubMed ID: 33838549
[TBL] [Abstract][Full Text] [Related]
16. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
17. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
Brink DS
Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
[TBL] [Abstract][Full Text] [Related]
18. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
Alejo-Valle O; Weigert K; Bhayadia R; Ng M; Issa H; Beyer C; Emmrich S; Schuschel K; Ihling C; Sinz A; Zimmermann M; Wickenhauser C; Flasinski M; Regenyi E; Labuhn M; Reinhardt D; Yaspo ML; Heckl D; Klusmann JH
Blood; 2022 Feb; 139(5):651-665. PubMed ID: 34570885
[TBL] [Abstract][Full Text] [Related]
19. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
20. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
